Menu

Top Stories

Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1 Antitrypsin Treatment

Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1 Antitrypsin Treatment
Friday, July 21, 2017
Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, today announced that the Company has submitted to the U.S. Food and Drug Administration (FDA) for review a proposed pivotal Phase 3 protocol for its proprietary inhaled Alpha–1 Antitrypsin (AAT) therapy (Inhaled AAT) for the treatment of Alpha–1 Antitrypsin Deficiency (AATD). The proposed...
Divider

Foundation president and CEO urges Alphas to find their place in the Alpha-1 Community

Thursday, June 29, 2017
CHICAGO, Illinois – Henry Moehring, president and CEO of the Alpha–1 Foundation, presided over the 26th and largest National Education Conference of the Alpha–1 community since its inception, he said in his Foundation update...
Divider

Alpha-1 Foundation Accepting Proposals for the John W. Walsh Translational Research Award in Alpha-1 Antitrypsin Deficiency

Wednesday, June 28, 2017
The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide. This award is named after John W. Walsh, who dedicated his life’s work to finding...
Divider

Barbara Pusey honored in memoriam at Alpha–1 awards and recognition night

Monday, June 26, 2017
Barbara Pusey, who was the first AlphaNet Coordinator for the augmentation therapy marketed in the United States as Zemaira and was a major influence in building the AlphaNet Zemaira program into what it is today, was recognized posthumously, with...
Divider

Grifols announces $1 million grant to support Alpha-1 Foundation’s John W. Walsh Research Fund

Monday, June 26, 2017
Washington, DC  — Grifols announced that it will award a million-dollar grant to support the John. W. Walsh Research Fund, the Foundation’s peer-reviewed research program named in honor of Walsh, the Foundation’s co-founder...
Divider

More Than 600 to Hear Top World Experts on Alpha-1 at National Conference in Chicago

Monday, June 5, 2017
CHICAGO, June 5, 2017 – More than 600 people with Alpha–1 Antitrypsin Deficiency – the most common known genetic cause of chronic obstructive pulmonary disease (COPD) – along with their family members, caregivers and...
Divider

Alpha highlights research participation for Rare Disease Day

Tuesday, February 28, 2017
Ken Benson is a firm believer in research. Ken Benson For years, the lung- and liver-affected Alpha has allowed scientists to closely examine how his body works in study after study. He has participated in the COPDGene study at the...
Divider

Alpha-1 Foundation honors co-founder John W. Walsh with title of Director Emeritus

Wednesday, February 15, 2017
Alpha-1 Foundation Co-founder and visionary John W. Walsh has been named a Director Emeritus of the Board of Directors at the February 3, 2017 Board meeting. John W. Walsh “We have now passed the one-year anniversary of the accident...
Divider

Scientists battle in court over lucrative patents for gene-editing technology

Tuesday, December 6, 2016
The high-stakes fight over who invented a technology that could revolutionize medicine and agriculture heads to a courtroom Tuesday. Emmanuelle Charpentier (left) and Jennifer Doudna A gene-editing technology called CRISPR-cas9 could be...
Divider

Congress passes 21st Century Cures Act, boosting research and easing drug approvals

Monday, December 5, 2016
Congress passed sweeping legislation Wednesday that boosts funding for medical research, eases the development and approval of experimental treatments, and reforms federal policy on mental health care. The 94 to 5 Senate vote Wednesday followed...
Divider

RAPID trial extension study finds augmentation therapy slows disease progression, supports early intervention

Friday, December 2, 2016
The medical journal The Lancet Respiratory Medicine on Thursday, Dec. 1, published findings of the RAPID Open Label Extension study of augmentation therapy for patients with emphysema and Alpha-1 Antitrypsin Deficiency. N. Gerard...
Divider

House overwhelmingly passes 21st Century Cures bill

Thursday, December 1, 2016
WASHINGTON — The House overwhelmingly passed a far-reaching measure on Wednesday to increase funding for research into cancer and other diseases, address weaknesses in the nation’s mental health systems and help combat the prescription...
Divider

Arrowhead halts clinical trial of Alpha-1 liver drug candidate, plans to move ahead with subcutaneous AAT program

Wednesday, November 30, 2016
Arrowhead Pharmaceuticals has halted clinical trials of several potential drug therapies using its EX1 delivery system, including ARC-AAT, which had been showing good results in clinical trials to treat Alpha-1 liver disease, the company said in a...
Divider
1234567

Article Search

Enter keywords in text box and click Search button for results.